Saatja: Günter Braun <
[email protected]>
Saaja: SM Info
Teema: AW: Proposal for a Clinical Study regarding the telemedicine-supported diagnosis and treatment of the Chronic Kidney Disease at early stages
An: '
[email protected]' <
[email protected]>
Betreff: Proposal for a Clinical Study regarding the telemedicine-supported diagnosis and treatment of the Chronic Kidney Disease at early stages
Dear Sir or Madam,
In my proposal sent today at 10:00 my address was not complete.
The complete address is:
Dr. Guenter Braun
President and CEO
Aristo Telemed AG
Edmund-Mueller-Str. 2
D-82041 Oberhaching
Tel. +49 89 6252818
Fax +49 89 6252719
Mob. +49 171 5573686
[email protected]
Von: Günter Braun [mailto:
[email protected]]
Gesendet: Dienstag, 25. August 2020 10:00
An: '
[email protected]' <
[email protected]<mailto:
[email protected]>>
Betreff: Proposal for a Clinical Study regarding the telemedicine-supported diagnosis and treatment of the Chronic Kidney Disease at early stages
Dear Mrs. Sikkut, you are the minister of Health and Social Affairs in Estonia,
dear Sir or Madam,
The COVID-19 pandemic in Estonia is part of the ongoing worldwide pandemic<https://en.wikipedia.org/wiki/COVID-19_pandemic> of coronavirus disease 2019<https://en.wikipedia.org/wiki/Coronavirus_disease_2019> (COVID-19) caused by severe acute respiratory syndrome coronavirus 2<https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2> (SARS-CoV-2). The virus was confirmed to have spread to Estonia<https://en.wikipedia.org/wiki/Estonia> when the first case was confirmed in Tallinn<https://en.wikipedia.org/wiki/Tallinn> on 27 February 2020. By 11 March, 15 people in Estonia had been diagnosed with the virus. All of them had been infected outside the country, mostly in Northern Italy<https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Italy>. On 12 March, the first cases of locally transmitted infections emerged, and on 13 March, the Estonian government declared a state of emergency until 1 May 2020. As a result, all schools and universities were closed, and all public gatherings banned, including sports and cultural events. As of 20 August, the total number of confirmed cases in the country was 2,227, of which 2,059 had recovered and 63 had died. Based on the emergency measures, meanwhile the further spreading of COVID 19 in Estonia has been stopped and the pandemic is under control.
That enables us now to submit our proposal for a clinical study regarding the telemedicine-supported diagnosis and treatment of the Chronic Kidney Disease at early stages. We therefore suggest that at the beginning of the study the Estonian Ministry of Health nominates the Estonian study participants based on current diagnoses for diabetes and hypertension of MDs or hospitals. As part of the telemedicine-supported study is the regular monthly transmission of the status of the triggering diseases diabetes and hypertension, the participants of the study should have access to a personal computer or a smartphone. Even most elderly persons have that today.
Regarding Canada and the United States, for which the study had initially been developed, our representative in the United States had told me recently that the COVID-19 pandemic there will not allow a successful submission before September or October 2020 Even that seems optimistic these days. As the situation regarding the COVID-19 pandemic in many European countries is much better we had decided to serve Europe first.
From the Health Ministry of another EU member state we had already received congratulations for the study design. The study allows the participants an effective telemedicine-supported treatment of diabetes and hypertension and will thus also make sure that a theoretically possible later infection with COVID-19 (second wave) will not lead to a life-threatening situation. The first step to begin with the study is the nomination of the participating person. For the study we do not need the names and addresses of the study participants. In order to comply with data protection and privacy rules we suggest that your ministry provides the study participants with pseudonyms like ES1, ES2 … . That is sufficent for the study. Only your ministry knows the identity behind the pseudonyms. The proposal and my professional CV are attached.
We look forward to work with you.
Best regards
Guenter Braun
:
Saatja: Günter Braun <
[email protected]>
Saadetud: 25.08.2020 10:59
Adressaat: SM Info <
[email protected]>
Teema: Proposal for a Clinical Study regarding the telemedicine-supported
diagnosis and treatment of the Chronic Kidney Disease at early stages
Dear Mrs. Sikkut, you are the minister of Health and Social Affairs in
Estonia,
dear Sir or Madam,
The COVID-19 pandemic in Estonia is part of the ongoing of (COVID-19)
caused by (SARS-CoV-2). The virus was confirmed to have spread to when
the first case was confirmed in on 27 February 2020. By 11 March, 15
people in Estonia had been diagnosed with the virus. All of them had been
infected outside the country, mostly in Northern . On 12 March, the first
cases of locally transmitted infections emerged, and on 13 March, the
Estonian government declared a state of emergency until 1 May 2020. As a
result, all schools and universities were closed, and all public
gatherings banned, including sports and cultural events. As of 20 August,
the total number of confirmed cases in the country was 2,227, of which
2,059 had recovered and 63 had died. Based on the emergency measures,
meanwhile the further spreading of COVID 19 in Estonia has been stopped
and the pandemic is under control.
That enables us now to submit our proposal for a clinical study regarding
the telemedicine-supported diagnosis and treatment of the Chronic Kidney
Disease at early stages. We therefore suggest that at the beginning of
the study the Estonian Ministry of Health nominates the Estonian study
participants based on current diagnoses for diabetes and hypertension of
MDs or hospitals. As part of the telemedicine-supported study is the
regular monthly transmission of the status of the triggering diseases
diabetes and hypertension, the participants of the study should have
access to a personal computer or a smartphone. Even most elderly persons
have that today.
Regarding Canada and the United States, for which the study had initially
been developed, our representative in the United States had told me
recently that the COVID-19 pandemic there will not allow a successful
submission before September or October 2020 Even that seems optimistic
these days. As the situation regarding the COVID-19 pandemic in many
European countries is much better we had decided to serve Europe first.
From the Health Ministry of another EU member state we had already
received congratulations for the study design. The study allows the
participants an effective telemedicine-supported treatment of diabetes
and hypertension and will thus also make sure that a theoretically
possible later infection with COVID-19 (second wave) will not lead to a
life-threatening situation. The first step to begin with the study is the
nomination of the participating person. For the study we do not need the
names and addresses of the study participants. In order to comply with
data protection and privacy rules we suggest that your ministry provides
the study participants with pseudonyms like ES1, ES2 … . That is
sufficent for the study. Only your ministry knows the identity behind the
pseudonyms. The proposal and my professional CV are attached.
We look forward to work with you.
Best regards
Guenter Braun
Dr. Guenter Braun
President and CEO
Aristo Telemed AG
Edmund-Mueller-Str. 2
D-82041 Oberhaching
Proposal for a study regarding the diagnosis and treatment of the Chronic Kidney Disease at early
stages, i.e. the diagnosis and treatment of the triggering diseases Diabetes and Hypertension.
Aristo Telemed had developed that in a project that had been partially funded by the Bavarian Health
Ministry 2010-2012 based on literature by the National Kidney Foundation (USA), USRDS Annual
Reports, NHS reports and medical guidelines from different countries regarding diagnosis and
treatment of CKD and discussions with a family doctor in Ingolstadt and nephrologists in Ingolstadt
and Munich.
As of 2020 Estonia has a population of 2.8 million residents. According to the IDF there is a
prevalence diabetes of 6.2% in Estonia’s adult population. The total adult population of Estonia is
948,700. That means approximately 59,000 persons. In a study published 2011 arterial hypertension
affects approximately 20 - 30% of the adult population in modern societies and its prevalence has
been predicted to increase as high as 60% in 2025. Among European countries Estonia stands out
with high prevalence of hypertension, affecting more than one third of the adult population.
Diabetes and Hypertension are also triggering diseases for the Chronic Kidney Disease (CKD). CKD is a
severe disease that does not hurt and can therefore often develop almost unnoticed to higher stages
with enormous consequences for the patient. Therefore it makes a lot of sense to treat CKD at early
stages in a telemedicine-supported project. Telemedicine will support the patient in his or her
endeavour to avoid the development of CKD to higher stages and other severe diseases.
Diabetes and Pre-Diabetes are in most cases be treated by lifestyle, exercise, and dietary changes so
that only a fraction of those require medical treatment. Regarding the non-adherence rate, e.g. in
Estonia probably less than 4,000 people would be affected. As both Diabetes, Pre-Diabetes and
Hypertension may cause CKD, the number of patients who require medical treatment cannot finally
be provided. So this proposal can only provide the cost per patient.
Regarding the use of antihypertensive drugs, Prof. John Toon (GeorgiaTech Atlanta) had recently
published a research report in the journal Lancet that Thiazide diuretics demonstrate better
effectiveness and cause lower side effects than ACE inhibitors.
The following cost per patient will apply. They are based on proposals by the respective companies:
Medipense is located in Quebec, Canada, Beurer is located in Germany.
Medipense Automatic Dispenser € 3,250.00
supports the adherence of the patient to the prescription
of his family doctor or specialist doctor.
Cost for each patient including RxPense, initial training and
deployment, configuration, monitoring, support and
management for a period up to one year After that period
annual maintenance and support is 20%
Beurer Bluetooth Upper Arm Blood Pressure Monitor for
Self-testing per patient € 20.43
Beurer Bluetooth Glucose Monitor for self testing
Cost per unit € 18.02
Test strips € 6.87
Lancets € 1.29
Overall cost of Beurer equipment per patient € 46.61
The values for blood pressure and glucose are regularly measured by the patient, e.g. once a month
and transmitted via the patient’s smartphone to his/her family doctor or nephrologist and
To Aristo Telemed for the evaluation of the study.
Cost of Aristo Telemed for project management and evaluation of the project results
€ 263.25
Overall cost of the study per patient € 3,559.86
Above cost are payable to Aristo Telemed IBAN: DE56 7007 0024 0886 9182 00
BIC: DEUTDEDBMUC
They are due as follows:
20% with the order by the customer
70% when the devices have been delivered to the Latvian Ministry of Health
for distribution to participating patients
10% when the study has been evaluated
All cost by equipment manufacturers will be paid by Aristo Telemed when the devices have been
delivered to the Health Ministry of Latvia for distribution to the patients participating in the study to
their accounts upon sending an invoice to Aristo Telemed by mail or email.
Based on our experience with previous clinical studies in Europe we suggest
An operational time of the study 12 months
Measurements of glucose and blood pressure monthly
The medicines for the treatment are prescribed by the patient’s physician and provided by
pharmacies in blisters which are compliant with the Medipense dispenser.
To comply with data protection and privacy rules the names and addresses of patients are not
needed or used in the study. Instead we propose to use pseudonyms like LAT1, LAT2, LAT3, etc.
which are allocated to the patients and may be used by Aristo Telemed for the evaluation of the
study. Only the Ministry of Health Latvia knows the personal data behind the pseudonyms.
Dr. Guenter Braun
President and CEO
Aristo Telemed AG
Edmund Mueller Str. 2
D-82041 Oberhaching
Tel. +49 89/6252818
Fax +49 89/6252719
Mob. +49 171/5573686
[email protected]
CV Dr.-Ing. Guenter Braun
From 2010 to 2012 Aristo Telemed had developed a telemedicine-supported method for the diagnosis
and treatment of the Chronic Kidnev Disease (CKD) at early stages in a project that had been partially
funded by the Bavarian Health Ministry. The development was based on literature by the National
Kidney Foundation (USA), USRDS Annual Data Reports, NHS (UK) reports and medical guidelines
from different countries as well as discussions with a family doctor in Ingolstadt and nephrologists in
Ingolstadt and Munich. Later it had been refined and translated to English.
In December 2019 Guenter Braun had a phone call with Aristo Telemed’s representative in the United
States. He suggested to submit our proposals for CKD first to Canadian provinces. After that he will be
available to address private insurances in the United States and finally the Centers for Medicare and
Medicaid Services. He had also established excellent contacts to Canada supported by the Canadian
trade commissioner to Germany and based on Alberta-Bavaria workshops in Munich 2018 and 2019.
Canada also seemed to be interested to participate in the harmonization of social laws in the EU
based on the free trade agreement CETA between Canada and the European Union
In January 2020 he had been asked by the Centers of Medicare and Medicaid Services to nominate
himself for a CMS Expert Panel for the development of a Quality Measure Assessing Delay in
Progression of the Chronic Kidney Disease at Yale University which he did. That had also been part of
the project for the Bavarian Health Ministry.
Regarding the „Digitization” in healthcare and care for elderly persons, Aristo Telemed (AT) supported
and in many cases still supports startups and established companies from Canada, Germany,
Hungary, Israel, Latvia, Poland, Russia, Ukraine and the USA regarding international healthcare
market access for
a fall sensor for seniors, that provides an alarm to a predefined phone in case of an
unintended fall.
a method for non-invasive treatment of ADHD in children who show verbal and learning
deficits
an intelligent electronic stethoscope for use by an MD or at home that is synchronized with a
smartphone e.g. for the early detection of lung infections. It analyzes the recorded sounds,
can detect abnormalities and transmits the sounds and its suggested diagnosis to the patient’s
MD for further consultation.
An innovative RFID chip that can be attached to medical devices and surgical instruments
which tolerates high temperatures that are applied in sterilization processes. That chip helps
personnel in hospitals to find medical devices and surgical instruments in hospitals easier.
Worn on a bracelet by patients it helps finding those patients in hospitals if required.
An innovative method to investigate arteries and veins in order to avoid heart attacks and
strokes.
Further health apps e.g. for the support of psychiatric patients will follow soon.
A comparative study regarding different methods for an early detection of prostate cancer had
been prepared together with medicine professors in Cologne, Aachen and Hamburg will be
started soon. A high-ranking member of the German organization to which we will submit it
had already told me that they intend to fund that research as soon as the request will be
submitted.
With a Canadian partner from Calgary AT had prepared a ZIM-Project in which emotions of patients
calling their MDs will be evaluated to provide additional information for the MDs regarding the patient’s
condition.
In 2013 Guenter Braun had developed and proposed a modern governing structure for the German
Health system but nobody seemed to be interested. So he decided to become a candidate for the
elections to the European parliament 2019 and was nominated as a candidate by the CSU in
November 2018. In April 2019 Guenter Braun had discussed differences between the Austrian and
German Social Laws with the deputy director of the Main Association of Austrian Social Security
Institutions whom he had known since the introduction of the e-card in Austria in 2005 and the joint
participation at the WSIS 2005 in Tunis in autumn 2005. However, he did not believe that the German
or Austrian social law can be a role model for other EU countries. He had been invited to the upbeat of
the election campaign in Schrobenhausen on April 29th 2019 with Manfred Weber (the leader of the
E.P.P) and Prof. Angelika Niebler for the elections to the European parliament. He had been
interviewed on stage in front of some 1,000 CSU members and said he would like to harmonize social
laws in the EU member states to avoid barriers in the European Economic Area so that all EU member
states can participate equally in advances in healthcare. In detail he suggested to introduce a modern
management structure in European healthcare based on goals similar to what he had developed and
introduced successfully with his team at Siemens AG worldwide almost 20 years ago and which
(business development) and he had lectured at Munich University and the University for Applied
Sciences Cologne from 2012 to 2018.
Even though the instruments (e.g. balanced scorecards) are the same, the goals in healthcare would
not be profit or company value but the quality of life and the healthy life years of the population in the
EU member states.
That was very well received by the audience. Later he supported Manfred Weber and Angelika Niebler
in their campaign with these personal goals (in German) that he sent to all Bavarian MDs networks,
hospitals, health insurers and medium-sized companies and achieved an excellent result for the CSU
in Bavaria. At the end of the rally event for the European parliament in Munich with Manfred Weber
and several European heads of state to which he was invited again, Angelika Niebler told him that we
will soon meet again (in Brussels). In October 2019 the office of the EU commission asked him to
apply with his professional CV as an advisor to the EU commission which he did. Due to travel
restrictions, however, going to Brussel will not be possible before August 2020.
Still another project will also be started soon. Its purpose is to make sure that a patient can at all times
reach his family doctor by telephone. This is particularly important with single practices in rural areas
and could certainly be exported to many countries.
In April 2009 Dr. Braun founded the Aristo Telemed AG (AT). He holds all 50,000 shares of the
company.
In 2008 Dr. Braun was elected head and project manager of the National German Project Group
„ProTelemonitoring“ at the VDE in Frankfurt with all important stakeholders of the industry, including
several large health insurers, university hospitals, MDs, the German Health Ministry, and the federal
joint committee who decides what German health insurers must compensate. The project group
determined the benefits of telemedicine/telemonitoring support for patients with severe chronic
diseases in a metastudy for the BMBF (German Ministry for Education and Research). The evaluation
of benefits and proposals for the compensation of telemedicine were provided for diabetes, chronic
heart failure, chronic wounds and COPD. A brochure with the results can be obtained from the VDE.
In 2007 he left Siemens as ICN Enterprise Systems should be sold to an unknown buyer. It had
already significantly reduced investments and development expenses and had sold its campus in
Santa Clara/California to achieve a positive result. A separate spin-off of his group that would have
been financed by a well-known international investor based on a positive due diligence was opposed
by his peer as it was said that Healthcare Solutions was „the pearl of the company“, and without it ICN
Enterprise Networks could not be sold at all. Two meetings with the Siemens president Heinrich von
Pierer were positive but he said he needed to ask the board of directors for their consent. The
following meeting of the board of directors end of January 2007, however, was focused on the
Siemens bribery affair only and did not decide about the sales of the Healthcare Solutions Unit. So he
and also all members of his team left Siemens.
In 2002 he had suggested his peer to start a new business field at Siemens ICN Enterprise Networks
that should care about the upcoming use of ICT in healthcare systems. His boss reacted promptly and
asked him to build and lead the new unit. If he did he could be relieved of some of his other
responsibilities to date as he wanted. He also got permission to hire suitable personnel from any
Siemens organization for his new unit. The new business unit “Healthcare Solutions” started
operations beginning of 2003 while he kept contact with the universities (CAMPUS), Fraunhofer and
the eFinance Lab, and the Siemens customers as much as possible. Responsibilities of the global
Business Unit Healthcare Solution were business planning, turnover, and results as well as the
support of 40 national Siemens ICN units regarding customer support, sales, project management,
and services. Talks and negotiations with high-ranking deciders of governments or important health
institutions, e.g. the government of Slovenia, the US Department of Health and the speaker of the
House of Representatives Newt Gingrich in Washington D.C. USA on interoperability issues between
European and US electronic health records, the board of Health Infoway Canada in Toronto, the
Director of the NSW Cabinet Office Roger Wilkins in Sydney, the Director of Health in New Orleans Dr.
Kevin Stephens, and the board of the VHA Southwest (Hospitals of the Veterans Health Association)
in Dallas were part of his job. In New Orleans he had been interviewed by Lousiana TV together with
his US team member and Dr. Stephens regarding the benefit of electronic health cards which was
transmitted nationwide. For his stays in the US he had an office in Malvern, Pennsylvania. Since 2002
he had also been involved with the introduction of eHealth (HealthIT) in Germany (eGK, ePA), Austria
(ecard) and Switzerland. In that context he had also met several top politicians from different German
“Bundesländer” including Ursula von der Leyen at different fairs. At that time she was Minister for
Health in Niedersachsen. For his regular talks with the German Health Ministry he could use a
Siemens office in Berlin at the Gendarmenmarkt. In November 2005 he represented Siemens together
with a member of the Siemens board at the World Summit on IT in Tunis (WSIS 2005).
In 2000 he had been selected by Siemens ICN for leading a new field “innovation management” at the
division for cooperation with universities and research organizations that was regarded necessary by
the Siemens board. Focus was on Germany and the US, e.g. Georgia Tech Atlanta, SCR Princeton,
UC Berkeley and others. He gave a well-received lecture on his experience with business consultants
at the Wharton Business School (University of Pennsylvania). Together with different Siemens board
members he became a member of the steering committees of the technical universities Munich and
Berlin, met regularly with several German universities and research organizations, e.g. Fraunhofer
(CAMPUS-Meetings). He became also responsible for the evaluation of innovative ideas by startup
companies for Siemens Venture Capital. There was a partial overlap of these tasks with his
responsibility for business strategy.
1997 he joined the business communications division of Siemens where he became responsible for
business strategy and business development. With his department, he was given global responsibility
for the Siemens ITC strategy in all countries where Siemens ICN operated. With his new department
he became responsible for market analysis, business strategy, strategic and operative planning,
business development, benchmarking, target agreements for all managers, and the development and
ongoing maintenance of balanced scorecards, internal and external communication of goals, strategy
and customer benefits as well as total quality management issues. His responsibility also included
presentations and discussions with Siemens customers and their worldwide organization JUST
(Joint Users of Siemens Technology). It included many large companies in various countries. In
particular he often met and discussed with Swiss enterprises including the Central Swiss Power Plants
and several large banks. He was also a founding member of the eFinance Lab at Frankfurt University.
From 1986 to 1997 he worked for Daimler-Benz Aerospace in the satellite business (Dornier Satellite
Systems, today Airbus Space and Defense) where he was responsible for advanced antenna and
microwave technologies, innovations, sales and strategy in satellite communications and earth
observation technologies, and planning of planetary missions (e.g. Cassini/Huygens) in two branches
of the company in Southern Germany. Regarding SAR antennas for earth observation and planetary
missions he negotiated with the JPL Pasadena. With his department, he led and submitted various
successful proposals to ESA/ESTEC, and the German Research Ministry regarding advanced satellite
antennas and microwaves. Within the EU he participated in COST (Cooperation in Science and
Technology) meetings in various EU countries.
He was also successful with a proposal to the US Department of Defense for planning a Space Shuttle
mission to test and establish a measurement method to detect the launch of missiles and rockets.
He also established mm-wave technologies at his department. On that basis his department
successfully submitted proposals for satellite missions for environmental measurements e.g. ozone
and trace gases in the atmosphere and on ground. Considering that various technologies for space
applications could also be used to solve challenges in other industries, he convinced the CEO to make
an according announcement in the company which led to several interesting results. The winner was
the usage of rotating SAR antennas on helicopters which was then built and tested by Eurocopter and
showed promising results for obstacle warning of helicopters even under bad weather conditions.
Therefore it had the potential to significantly reduce the number of fatal helicopter accidents often
caused by collisions with wires and other obstacles. The solution “Heliradar” was submitted by several
organizations to the German President’s office and selected as one of five candidates for the German
Future Award 1997 (Deutscher Zukunftspreis).
G. Braun published the results of his research in various national and international research
magazines and presented those on various international symposia in Europe and the US. On one of
these occasions he received the privilege of a personal guided tour through the Hughes Corp. in Los
Angeles. Hughes was the world’s largest satellite manufacturer, and the tour included the impressive
satellite integration facility. Finally, in 1997 he proposed a strategy to develop and market a new
generation of communication satellites and was supported by about 40 DSS executives, the German
Research Ministry and the DSS employee organization. As the CEO denied to accept the strategy and
as he had a good job offer from Siemens, he left Dasa/DSS (1997).
From 1982 to 1986 he worked as a Research Fellow and Associate Professor at the University of the
Bundeswehr in Neubiberg near Munich. His research and development activities included mobile
communications, radar and medical technologies. For his research on noise optimization of oscillators
in mobile communications and radar systems he received the Dr.-Ing. degree with summa cum laude
in 1985. He presented his findings at the 1986 lEEE International Symposium on Circuits and Systems
in San Jose/California.
1974 to 1982 he worked for Siemens in Munich. Before he started 1977 working for Siemens in the
development of radio relay systems (2 to 15 GHz) and research on innovative semiconductor chips for
radio systems (MMICS etc.), Siemens had offered him a two-year trainee program (Ingenieurkreis)
where he was given the opportunity to work in different divisions of the company which he could
choose himself. Starting 1974, he chose to work on new semiconductor and printed circuit
technologies, the product management of a new radio relay system, and the sales of radio relay
systems in Africa and Southeast Asia. Negotiations with customer organizations took place in London
and Tripolis/Libya. He left Siemens 1982 to proceed with research work on his intended Dr.-Ing.
degree.
Guenter Braun had studied Electrical and Electronics Engineering at the Technical University Munich,
Germany and Southampton University, UK. He received the Dipl.-Ing. degree with summa cum laude
in 1974. He had received a scholarship from the Studienstiftung des deutschen Volkes.
Besides his job, in 1977 he founded a model railway shop in Munich that he led successfully until
2009. The shop had 3 to 5 employees and worldwide suppliers and customers in many countries of
the EU but also in the USA, Hongkong, Japan and China.
Publications, Miscellaneous:
- Over 50 scientific publications and conference lectures regarding communications and space
technology, Total Quality Management (EFQM, ISO9001), innovation management, HealthIT
und Telemedicine/Telemonitoring.
- Author, co-author and editor of professional books and brochures regarding aerospace
research, HealthIT and Telemonitoring.
- Member of the selection committees of the Studienstiftung des deutschen Volkes and the
Max-Weber-Programm for the award of scholarships for highly gifted students.
- 1986 Development of a research report for the Bavarian State Chancellery for funding of a
Bavarian startup enterprise regarding microwave technology.
- Nomination for the Deutscher Zukunftspreis of the German President Herzog 1997 with the
project HeliRadar.
- Since 2002 member of the research committee, the operative steering body of the Muenchner
Kreis, responsible for Healthcare and member of the working groups digitization and mobility
- Head of the program committees and chairman of the HealthIT congress February 2005 and
the conference Telemonitoring in July 2009 in Munich und Member of the program committee
for the preparation of the conference Digitizing and Big Data in Healthcare May 2018 in
Munich.
- From winter term 2012 until 2018 lectures regarding HealthIT infrastructure and Applications
as well as business development (e.g. for hospitals) in the extra-occupational master and
bachelor courses at the University for Applied Sciences Cologne and 2013 also at the
bachelor course Health Economics at Munich University.
- 2017-2018 he received a contract for a Research Report from the Technology Agency of
Latvia (LIAA) for the „European Regional Development Program“ for the development funding
of a Latvian startup enterprise.
- From 1977 to 2011 he had been member of the board of directors of the Muenchner
Baugenossenschaft in Muenchen-Laim with some 1000 flats, 20 years thereof until 2010 as its
chairman.